An observational study in Squamous Cell Head and Neck Carcinoma, sponsored by Groupe Oncologie Radiotherapie Tete et Cou. Completed at 18 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-03.
Sponsored by Groupe Oncologie Radiotherapie Tete et Cou · Observational
The ending of this study is to describe the effect of febrile neutropenia on patients who receive a chemotherapy by docetaxel+cisplatin+fluorouracil(TPF).
In this study we will describe
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 130 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Groupe Oncologie Radiotherapie Tete et Cou is the lead sponsor of 32 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
people who undergo first traitement by chemotherapy (docetaxel+cisplatin+-FU) for head and neck cell carcinoma, whom age is over eighteen,
Exclusion Criteria:
biologic blood counts
evaluation of medical status evaluation of hematologic toxicity description of clinic toxicity: fever, sepsis..
Time frame: blood test before every chemotherapy up to 4 months
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Groupe Oncologie Radiotherapie Tete et Cou